The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) vs LEN+DEX in relapsed/refractory multiple myeloma (R/R MM).

Nimer  Alsaid

No Relationships to Disclose

Ali  McBride

No Relationships to Disclose

Amit Balkrishna  Agarwal

Employment - Celgene

Consulting or Advisory Role - Amgen; Millennium

Speakers' Bureau - Janssen; Novartis; Onyx

Abdulaali  Mutairi

No Relationships to Disclose

Faiz  Anwer

No Relationships to Disclose

Ivo  Abraham

No Relationships to Disclose